|
110 |
Quality Risk Management: What’s new in ICH Q9(R1)?
|
관리자 |
2025-04-01 |
527 |
|
109 |
FDA issues Warning Letter due to GMP Violations at Chinese Drug Manufacturer
|
관리자 |
2025-04-01 |
358 |
|
108 |
A Risk-based Approach To Filter Integrity Testing Annex 1 Requirements For Biologics DS
|
관리자 |
2025-02-28 |
475 |
|
107 |
Pharmaceutical stability testing: An overview of stability
|
관리자 |
2025-02-28 |
473 |
|
106 |
2024 Trends In FDA Observations For Sterile Drug Manufacturers
|
관리자 |
2025-02-28 |
323 |
|
105 |
Ensuring Repeatable, Viable Surface Sampling In Aseptic Settings
|
관리자 |
2025-02-28 |
323 |
|
104 |
Incubating settle plates: Understanding growth patterns and when things are going wrong
|
관리자 |
2025-02-03 |
548 |
|
103 |
11 Key Contributing Factors For Maintaining Sterility Assurance
|
관리자 |
2025-02-03 |
1,054 |
|
102 |
Physicochemical Monitoring of Pharmaceutical Water
|
관리자 |
2025-02-03 |
444 |
|
101 |
Audit Readiness For Cell & Gene Therapy Companies
|
관리자 |
2025-02-03 |
423 |
